COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

被引：0
|
作者：
Naoise C. Synnott
David O’Connell
John Crown
Michael J. Duffy
机构：
[1] University College Dublin,UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research
[2] University College Dublin,UCD School of Biomolecular & Biomedical Science
[3] St. Vincent’s University Hospital,Department of Medical Oncology
[4] St. Vincent’s University Hospital,UCD Clinical Research Centre
来源：
Breast Cancer Research and Treatment | 2020年 / 179卷
关键词：
p53; TP53; COTI-2; Triple-negative breast cancer; Treatment; APR-246;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：47 / 56
页数：9
相关论文
共 50 条
  • [21] Piperine inhibits the growth and motility of triple-negative breast cancer cells
    Greenshields, Anna L.
    Doucette, Carolyn D.
    Sutton, Kimberly M.
    Madera, Laurence
    Annan, Henry
    Yaffe, Paul B.
    Knickle, Allison F.
    Dong, Zhongmin
    Hoskin, David W.
    CANCER LETTERS, 2015, 357 (01) : 129 - 140
  • [22] Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53
    Scarpetti, Lauren
    Oturkar, Chetan C.
    Juric, Dejan
    Shellock, Maria
    Malvarosa, Giuliana
    Post, Kathryn
    Isakoff, Steven
    Wang, Nancy
    Nahed, Brian
    Oh, Kevin
    Das, Gokul M.
    Bardia, Aditya
    ONCOLOGIST, 2023, : 358 - 363
  • [23] Targeting PP2A inhibits the growth of triple-negative breast cancer cells
    Uddin, Mohammed Hafiz
    Pimentel, Julio M.
    Chatterjee, Madhumita
    Allen, Joshu E.
    Zhuang, Zhengping
    Wu, Gen Sheng
    CELL CYCLE, 2020, 19 (05) : 592 - 600
  • [24] Triple- negative breast tumors are dependent on mutant p53 for growth and survival
    Dibra, Denada
    Moyer, Sydney M.
    Naggar, Adel K. El-
    Qi, Yuan
    Su, Xiaoping
    Lozano, Guillermina
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (34)
  • [25] The benefits of Didox in triple negative breast cancer treatment targeting mutant p53
    Sultana, Nahid
    Wilson, Elizabeth A.
    Shah, Khyati N.
    Elford, Howard L.
    Faridi, Jesika S.
    CANCER RESEARCH, 2020, 80 (16)
  • [26] Targeting mutant p53 with PK11007: A new approach for the treatment of patients with triple-negative breast cancer?
    Synnott, Naoise C.
    Bauer, Matthias R.
    Madden, Stephen F.
    Murray, Alyson M.
    Klinger, Rut
    O'Donovan, Norma
    O'Connor, Darran
    Gallagher, William M.
    Crown, John
    Fersht, Alan R.
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
    Bae, Soo Youn
    Nam, Seok Jin
    Jung, Yongsik
    Lee, Sae Byul
    Park, Byung-Woo
    Lim, Woosung
    Jung, Sung Hoo
    Yang, Hsien Wen
    Jung, Seung Pil
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 172 (02) : 437 - 444
  • [28] Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer
    Soo Youn Bae
    Seok Jin Nam
    Yongsik Jung
    Sae Byul Lee
    Byung-Woo Park
    Woosung Lim
    Sung Hoo Jung
    Hsien Wen Yang
    Seung Pil Jung
    Breast Cancer Research and Treatment, 2018, 172 : 437 - 444
  • [29] Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers
    Morrison, Chevaun D.
    Chang, Jenny C.
    Keri, Ruth A.
    Schiemann, William P.
    CELL DEATH & DISEASE, 2017, 8 : e2899 - e2899
  • [30] Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers
    Chevaun D Morrison
    Jenny C Chang
    Ruth A Keri
    William P Schiemann
    Cell Death & Disease, 2017, 8 : e2899 - e2899
12345